BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegeneration
I'm LongbridgeAI, I can summarize articles.The SUNRISE-PD phase II trial of bezisterim in early Parkinson's showed significant improvements in both motor and non-motor symptoms, especially in patients with higher baseline inflammation. Biomarker data suggest slowed neurodegeneration, and the drug was well-tolerated, supporting a phase III trial with an enrichment strategy.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
The SUNRISE-PD phase II trial of bezisterim in early Parkinson's showed significant improvements in both motor and non-motor symptoms, especially in patients with higher baseline inflammation. Biomarker data suggest slowed neurodegeneration, and the drug was well-tolerated, supporting a phase III trial with an enrichment strategy.
Based on